Pharmaceutical compositions containing, as active ingredient, granulocyte-colony stimulating factor mutant protein or transferrin fusion protein thereof
The present invention relates to a fusion protein in which transferrin is peptide-bonded to a terminal of a granulocyte-colony stimulating factor (G-CSF) protein or a G-CSF mutant protein in which the 116 th threonine is substituted with cysteine in the amino acid sequence of the G-CSF. Specifically, the granulocyte-colony stimulating factor (G-CSF) mutant protein of the present invention or the transferrin fusion protein thereof displays a significantly increased specific activity and blood stability, compared with the conventional human G-CSF, and has a higher purification efficiency than the conventional PEGylated G-CSF characterized by the extended half-life, so that it can be advantageously used for preventing or treating ischemic diseases or neutropenia.
1. A fusion protein in which transferrin is peptide-bonded to a G-CSF (granulocyte-colony stimulating factor) mutant protein in which the 116th threonine is substituted with a cysteine.
2. The fusion protein according to claim 1 , wherein the transferrin has the deletion of a signal peptide at the amino terminal region.
3. A method, comprising administering the fusion protein of claim 2 to a subject.
4. The fusion protein according to claim 1 , wherein the substituted cysteine forms a disulfide bond with the 17 th cysteine of the G-CSF mutant protein.
5. A method, comprising administering the fusion protein of claim 4 to a subject.
6. A method, comprising administering the fusion protein of claim 1 to a subject.
7. A fusion protein, comprising a transferrin protein that is peptide-bonded to a G-CSF (granulocyte-colony stimulating factor) mutant protein in which the 116th threonine is a substituted with a cysteine.
8. The fusion protein according to claim 7 , wherein the transferrin protein does not have a native signal peptide at the amino terminal region.
9. A method, comprising administering the fusion protein of claim 7 to a subject.
10. A fusion protein, comprising: a G-CSF (granulocyte-colony stimulating factor) mutant protein in which the 116th threonin is substituted with a cysteine; and
a transferrin protein peptide-bonded to the G-CSF mutant protein, wherein the transferrin has deletion of a signal peptide at the amino terminal region.
11. A method, comprising administering the fusion protein of claim 10 to a subject.